Literature DB >> 18251686

Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding.

Sjoerd H van der Burg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18251686     DOI： 10.1586/14760584.7.1.1

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


× No keyword cloud information.
  10 in total

1.  HPV16-E7 Protein T Cell Epitope Prediction and Global Therapeutic Peptide Vaccine Design Based on Human Leukocyte Antigen Frequency: An In-Silico Study.

Authors:  Bahareh Bahmani; Zahra Amini-Bayat; Mohammad Mehdi Ranjbar; Nahid Bakhtiari; Amir-Hassan Zarnani
Journal:  Int J Pept Res Ther       Date:  2020-06-27       Impact factor: 1.931

2.  Response definition criteria for ELISPOT assays revisited.

Authors:  Z Moodie; L Price; C Gouttefangeas; A Mander; S Janetzki; M Löwer; M J P Welters; C Ottensmeier; S H van der Burg; Cedrik M Britten
Journal:  Cancer Immunol Immunother       Date:  2010-06-15       Impact factor: 6.968

3.  Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.

Authors:  Kathryn Patton; Shahin Aslam; Jim Lin; Li Yu; Stacie Lambert; Glenn Dawes; Mark T Esser; Jennifer Woo; Sylvia Janetzki; Anu Cherukuri
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

4.  Estimating point and interval frequency of antigen-specific CD4+ T cells based on short in vitro expansion and improved poisson distribution analysis.

Authors:  Giulia Di Lullo; Francesca Ieva; Renato Longhi; Anna Maria Paganoni; Maria Pia Protti
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

5.  Harmonization of the intracellular cytokine staining assay.

Authors:  Marij J P Welters; Cécile Gouttefangeas; Tamara H Ramwadhdoebe; Anne Letsch; Christian H Ottensmeier; Cedrik M Britten; Sjoerd H van der Burg
Journal:  Cancer Immunol Immunother       Date:  2012-05-22       Impact factor: 6.968

6.  The immuno-oncology framework: Enabling a new era of cancer therapy.

Authors:  Axel Hoos; Cedrik Britten
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

7.  Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine.

Authors:  Liliane Maria Fernandes de Oliveira; Mirian Galliote Morale; Agatha A Muniz Chaves; Aline Marques Cavalher; Aline Soriano Lopes; Mariana de Oliveira Diniz; Alessandra Soares Schanoski; Robson Lopes de Melo; Luís Carlos de Souza Ferreira; Maria Leonor S de Oliveira; Marilene Demasi; Paulo Lee Ho
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

8.  Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Authors:  Cedrik Michael Britten; Sylvia Janetzki; Leah Ben-Porat; Timothy M Clay; Michael Kalos; Holden Maecker; Kunle Odunsi; Michael Pride; Lloyd Old; Axel Hoos; Pedro Romero
Journal:  Cancer Immunol Immunother       Date:  2009-03-04       Impact factor: 6.968

9.  Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.

Authors:  A Mander; C Gouttefangeas; C Ottensmeier; M J P Welters; L Low; S H van der Burg; C M Britten
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

Review 10.  Trial Watch: Peptide vaccines in cancer therapy.

Authors:  Fernando Aranda; Erika Vacchelli; Alexander Eggermont; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-11-04       Impact factor: 8.110
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.